Gout Market

DelveInsight’s “Gout Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Gout, historical and forecasted epidemiology as well as the Gout market trends in the United States, EU4 (Germany, France, Italy, Spain), and  the United Kingdom, and Japan.

The Gout market report provides current treatment practices, emerging drugs, Gout market share of the individual therapies, and current and forecasted Gout market size from 2019 to 2032, segmented by seven major markets. The report also covers current Gout treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, Spain), and the United Kingdom
• Japan

Study period: 2019–2032

Gout Treatment Algorithm and Disease Understanding

The DelveInsight’s Gout market report gives a thorough understanding of Gout by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Gout Overview

Gout Pain is a common form of inflammatory arthritis. It’s due to a crystal called uric acid. Gout causes pain and swelling in one or more joints. It typically affects the big toe. But it’s also found in other joints, including the knee, ankle, foot, hand, wrist and elbow. It is more common in men than in women. Gout usually develops in middle age.

Gout Diagnosis

Gout is assessed by physical examination, X-rays, and lab tests. Gout can only be diagnosed during a flare when a joint is hot, swollen, and painful and when a lab test finds uric acid crystals in the affected joint.

Gout Treatment

NSAIDs can reduce pain and swelling. Some people with kidney disease, stomach ulcers and other health problems are unable to take NSAIDs. Colchicine can reduce inflammation and pain if patient take it within 24 hours of a gout attack. Corticosteroids can relieve pain and swelling.

Gout Epidemiology

The Gout epidemiology section provides insights into historical and current Gout patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Gout report also provides the diagnosed patient pool, their trends and assumptions undertaken.

Key findings

The study conducted by Dehlin et al. (2020), the reported prevalence of gout in the USA was fairly high, with 3–4% of adults affected in 2007– 2008. Consistent with this estimate, in the 2015– 2016 National Health and Nutrition Examination Survey (NHANES), a stratified, multistage sample representative of the US adult population, the prevalence of self- reported, health professional-diagnosed gout was 3.9%.

Dehlin et al. (2020) also quoted that Gout is common in Europe, with studies in France, Germany, Greece, Italy, the Netherlands, Spain and the UK finding a gout prevalence ranging from 1% to 4% for the period 2003–2014, which has been confirmed in subsequent studies from other European countries.

The Gout epidemiology covered in the report provides historical as well as forecasted Gout epidemiology [segmented as Total Prevalence of Gout, Gender-specific Prevalence of Gout,  Age-specific Prevalence of Gout, and Diagnosed and Treatable Cases of Gout] in the 7MM covering the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan from 2019 to 2032.

Country-wise Gout Epidemiology

The epidemiology segment also provides the Gout epidemiology data and findings across the United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan.

Gout Drug Chapters

The drug chapter segment of the Gout report encloses the detailed analysis of Gout marketed drugs and late-stage (Phase III and Phase II) Gout pipeline drugs. It also helps understand the Gout clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Gout Marketed Drugs

lesinurad (Zurampic)

Lesinurad (Zurampic) is used to treat patients with gout. In gout, high levels of uric acid cause excess urate crystals to deposit in the joint, creating a hot, swollen, painful joint; the primary manifestation of gout. Lesinurad decreases uric acid by increasing the amount excreted in the urine.

Note: Detailed Current therapies assessment will be provided in the full report...

Gout Emerging Gout drugs

DYV700: Dyve

Dyve is a clinical-stage biotech company applying its proprietary transdermal drug delivery platform technology to a broad pipeline of clinical assets. Dyve’s lead asset is DYV700, for the treatment of pain associated with acute gout. In clinical and pre-clinical studies, Dyves transdermal drug delivery candidates have demonstrated a quick onset of action akin to an injection with extended duration and bioavailability akin to an oral pill. Dyve's goal is to offer a third route of drug delivery with emulsion-based therapies that are patient-friendly and clinically intuitive.

Note: Detailed emerging therapies assessment will be provided in the full report...

Gout Market Outlook

Treatment of pain and inflammation can be achieved with NSAIDs, colchicine, or corticosteroids (systemic or intra-articular). The choice of which treatment is the right one for a particular patient should be made on the basis of the patient’s co-morbid medical conditions, other medications, and side effect profile.

NSAIDS:  Commonly used NSAIDs during an acute gout attack include ibuprofen 800 mg three to four times daily or indomethacin 25 to 50 mg four times daily. Treatment should be discontinued when symptoms resolve

Colchicine:  Intravenous colchicine is associated with serious toxicities and side effects, so it should be used as an oral formulation only. High dose oral colchicine is generally poorly tolerated because of GI side effects. Lower doses are much better received and may be used in combination with NSAIDs.

Corticosteroids:  In patients with contraindications to NSAID use, corticosteroids are the next choice. Corticosteroids can be administered as an injection into the effected joint (intra-articular steroids) or given systemically (orally, such as prednisone or medrol). Intra-articular steriods are useful if only one or two joints are affected and the treating physician is proficient in injecting those joints.

Medicines to prevent recurrences of gout either block the production of uric acid or improve its removal. Examples include: allopurinol, febuxostat, pegloticase, probenecid.

According to DelveInsight, the Gout market in 7MM is expected to witness a major change in the study period 2019–2032.

Key findings

This section includes a glimpse of the Gout market in 7MM.

The United States: Gout Market Outlook

This section provides the total Gout market size and market size by therapies in the United States.

EU4 and the UK Countries: Gout Market Outlook

The total Gout market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan: Gout Market Outlook

The total Gout market size and market size by therapies in Japan are also mentioned.

Gout Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Gout market or expected to get launched in the market during the study period 2019–2032. The analysis covers Gout market uptake by drugs, patient uptake by therapies, and sales of each drug. 

This will help in understanding the Gout drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Gout Pipeline Development Activities

The Gout report provides insights into Gout Clinical Trails within Phase II, and Phase III stages. It also analyses Gout’s key players involved in developing targeted therapeutics.

Gout market clinical trial development activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for Gout emerging therapies.

Gout Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Gout domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Gout market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Gout market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Gout Market Report

• Descriptive overview of Gout, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the Gout epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for Gout, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
• Exhaustive analysis of the Gout market; historical and forecasted covering drug outreach in the 7MM
• Detailed patient-based market forecasting determines the trends shaping and driving the global Gout market

Gout Market Report Highlights

• In the coming years, the Gout market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Gout R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition  
• Major players are involved in developing Gout therapies. The launch of emerging therapies will significantly impact the Gout market
• A better understanding of Gout pathogenesis will also contribute to the development of novel therapeutics for Gout
• Our in-depth analysis of the Gout pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Gout Report Insights

• Patient-Based Market Forecasting
• Gout Therapeutic approaches
• Gout pipeline analysis
• Gout market size and trends
• Gout market opportunities
• Impact of Upcoming Gout therapies

Gout Report Key Strengths

• 10 year forecast
• 7MM Coverage
• Gout epidemiology segmentation
• Key cross competition
• KOL views
• Gout drugs uptake

Gout Report Assessment

• Current treatment practices
• Gout Unmet needs
• Gout pipeline product profiles
• Gout market attractiveness
• Gout Market Drivers
• Gout Market Barriers

Key Questions Answered In The Gout Market Report

Gout market insights:

• What would be the Gout market growth till 2032, and what will be the resultant market size in 2032?
•  What was the Gout drug class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the Gout total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
• What are the key findings of the market across 7MM, and which country will have the largest Gout market size during the forecast period (2019–2032)
• How would the unmet needs affect the Gout market dynamics and subsequent analysis of the associated trends?

Gout Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Gout?
• What is the historical and forecasted Gout patient pool in 7MM, and where can one observe the highest patient population and growth opportunities?
• What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, Spain), and the UK, and Japan?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for Gout in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Gout therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gout and its status, along with the challenges faced?

Reasons to Buy Gout Market Report

• The patient-based market forecast analysis will help in developing business strategies by understanding trends shaping and driving the Gout market
• Organize sales and marketing efforts by identifying the best opportunities for Gout in the US, EU4 (Germany, Spain, Italy, France), and the United Kingdom, and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors